Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Stocks of Local Interest
PG Energy Index
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ligand Pharm
(NQ:
LGND
)
123.34
USD
+1.06 (+0.87%)
Official Closing Price
Updated: 6:07 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Ligand Pharm
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
November 07, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat...
From
Business Wire News Releases
Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
November 05, 2019
From
PR Newswire
Ligand Reports Third Quarter 2019 Financial Results
November 05, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2019 and provided an operating forecast and program updates. Ligand...
From
Business Wire News Releases
Ligand to Report Third Quarter 2019 Results on November 5th
October 22, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and...
From
Business Wire News Releases
Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
October 15, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves...
From
Business Wire News Releases
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
September 23, 2019
Biopharmaceutical company is partnering with Sysmex Inostics to identify appropriate study candidates with the OncoBEAM™ ESR1 liquid biopsy test
From
GlobeNewswire News Releases
Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference
August 29, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York City. Presentation...
From
Business Wire News Releases
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
August 12, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative...
From
Business Wire News Releases
Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office
July 31, 2019
Proceeds will be used to fund Phase 2 ELAINE clinical trial, which is currently enrolling, to develop lasofoxifene as a potential precision medicine for metastatic breast cancer patients with ESR1...
From
GlobeNewswire News Releases
Lemelson Capital Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Calls on US Attorney to Investigate
July 30, 2019
As Ligand shares implode, reaching new multi-year low, Lemelson calls for intervention to protect investors
From
PR Newswire
Ligand Reports Second Quarter 2019 Financial Results
July 30, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates. Ligand...
From
Business Wire News Releases
Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
July 23, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a...
From
Business Wire News Releases
Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP
July 16, 2019
Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27[1] percent net return in 1H, 2019
From
PR Newswire
Ligand to Report Second Quarter 2019 Results on July 30th
July 15, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2019 financial results on July 30, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr, and...
From
Business Wire News Releases
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
July 10, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program...
From
Business Wire News Releases
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
July 08, 2019
SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.
From
PR Newswire
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
July 08, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and SQ Innovation AG today announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of...
From
Business Wire News Releases
ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
July 01, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration...
From
Business Wire News Releases
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
June 12, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an...
From
Business Wire News Releases
Ligand Licenses VER250840 to Cumulus Oncology
May 17, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a...
From
Business Wire News Releases
Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting
May 07, 2019
Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models.
From
GlobeNewswire News Releases
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
May 06, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections,...
From
Business Wire News Releases
Novan Completes Funding Transaction with Ligand Pharmaceuticals
May 06, 2019
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq:LGND)....
From
GlobeNewswire News Releases
Ligand Reports First Quarter 2019 Financial Results
May 02, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand management...
From
Business Wire News Releases
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
May 02, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol...
From
Business Wire News Releases
Ligand to Report First Quarter 2019 Results on May 2nd
April 18, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and...
From
Business Wire News Releases
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
March 21, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of Sage...
From
Business Wire News Releases
Ligand to Participate in Four Upcoming Investor Conferences
March 12, 2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:
From
Business Wire News Releases
Ligand Provides Highlights from Today’s Analyst Day Event
March 12, 2019
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business and financial growth outlook. Management provided...
From
Business Wire News Releases
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
March 11, 2019
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.